We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -10.00% | 9.00 | 8.00 | 10.00 | 9.00 | 9.00 | 9.00 | 670,146 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.06 | 35.01M |
From Apr 2019 to Apr 2024
TIDMREDX
RNS Number : 1856S
Redx Pharma plc
15 March 2021
REDX PHARMA PLC
("Redx" or "the Company")
Appointment of Joint Broker
Alderley Park, 15 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that it has appointed Panmure Gordon (UK) Limited to act as Joint Broker to the Company alongside WG Partners with immediate effect.
Hot Features
Premium
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/Chris Lee/David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886
2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPDKQBBCBKDQND
(END) Dow Jones Newswires
March 15, 2021 03:00 ET (07:00 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
